Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2022-05-11 00:00:00 ET · period of report 2022-05-09 · accession 0001567619-22-010091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-11 | 2022-05-09 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | M - OptEx | $0.95 | +90.9K | 241.7K | +60% | +$86.4K |
| DM | 2022-05-11 | 2022-05-09 | CTMX | McCarthy Sean A. | Pres, CEO, Dir | M - OptEx | $0.00 | -90.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-09 | M | A | 24,189 | $0.95 | 265,853 | D | — | — | (F1) Includes 75,000 restricted stock units. |
| 2 | Common | Common Stock | 2022-05-09 | M | A | 66,742 | $0.95 | 241,664 | D | — | — | (F1) Includes 75,000 restricted stock units. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-05-09 | M | D | 24,189 | $0.00 | 0 | D | $0.95 · — to 2023-02-25 | 24,189 Common Stock | (F3) 100% of the shares subject to the option are fully vested and exercisable. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-05-09 | M | D | 66,742 | $0.00 | 0 | D | $0.95 · — to 2023-02-25 | 66,742 Common Stock | (F3) 100% of the shares subject to the option are fully vested and exercisable. |